Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report on Pfizer, Merck, Bristol-Myers Squibb, Keryx and Pacira Pharmaceuticals Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, June 17, 2013 NEW YORK, June 17, 2013 /PRNewswire/ -- Today, Wall Street Reports announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), Bristol-Myers Squibb Company (NYSE: BMY), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), and Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Pfizer Inc. Research Report On June 12, 2013, Pfizer Inc. (Pfizer) announced that it has reached a $2.15 billion settlement with Teva Pharmaceuticals and Sun Pharmaceuticals for patent-infringement damages related to the launches of the generic Protonix in the US. Amy W. Schulman, Executive Vice President and General Counsel of Pfizer, said, "We are pleased with today's settlement, which recognizes the validity and value of the innovation that led to Protonix." Schulman added, "Protecting intellectual property is vital as we develop new medicines that save and enhance patients' lives." Pfizer will receive 64% of the compensation, and the remaining will be given to Nycomed, which is now part of Takeda. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/db02_PFE] -- Merck & Co. Inc. Research Report On June 12, 2013, Merck & Co. Inc. (Merck) commented on the NIDDK-NCI Workshop and the American Diabetes Association's (ADA) call for an independent review of data about the safety of incretin-based diabetes medicines, including GLP-1 analogs and DPP-4 inhibitors, such as Januvia (sitagliptin). Michael Rosenblatt, M.D., Chief Medical Officer of Merck, stated, "Nothing is more important to Merck than the safety of our medicines and the people who take them. We welcome opportunities to discuss the data that support the safety profile of sitagliptin in the treatment of adults with type 2 diabetes. Type 2 diabetes is a disease with serious consequences if left untreated." Rosenblatt continued, "We are committed to participating in an independent review of our data, and will join the ADA in planning for such an initiative." The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/400f_MRK] -- Bristol-Myers Squibb Company Research Report On June 12, 2013, Bristol-Myers Squibb Company (Bristol Myers Squibb) and AstraZeneca announced that they will continue to work with health authorities and scientific experts around the world to closely monitor the use of our GLP-1 receptor agonist and DPP-4 inhibitor through comprehensive surveillance programs to ensure patients and physicians have a clear understanding of the risk/benefit profile of these medications. This announcement came after the American Diabetes Association (ADA) called for incretin-based therapies manufacturers to make available the patient-level data from clinical trials for an independent analysis of pancreatic safety. The Full Research Report on Bristol-Myers Squibb Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/88a2_BMY] -- Keryx Biopharmaceuticals Inc. Research Report On June 3, 2013, Keryx Biopharmaceuticals, Inc. (Keryx) announced the presentation of updated efficacy and safety data from the Phase 3 long-term clinical trial of ZenerexZerenex (ferric citrate). Based on the efficacy results, Keryx determined that Zerenex is an efficacious and safe oral phosphate binder that controls serum phosphorus, increases iron stores as measured by serum ferritin and TSAT, and reduced the use of IV iron and ESAs, while sustaining hemoglobin as compared to the active control group. ZenerexZerenex met the pre-defined primary and key secondary endpoints for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis. The Full Research Report on Keryx Biopharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/27d7_KERX] -- Pacira Pharmaceuticals,Inc. Research Report On May 29, 2013, Pacira Pharmaceuticals, Inc. (Pacira) announced the findings from the completed first part of its Phase 2/3 clinical trial for the assessment of the use and administration of Exparel (bupivacaine liposome injectable suspension) as a single-dose injection femoral nerve block for total knee arthroplasty surgery (TKA). Dave Stack, President and CEO of Pacira, stated, "We are pleased with the interim analysis of the safety and efficacy of EXPAREL in this important orthopedic indication." Stack continued, "Based on the independent Data Safety Monitoring Board analysis, we believe that a single-dose injection of EXPAREL as a femoral nerve block can provide several days of analgesia without significant motor blockade. We look forward to initiating the Phase 3 portion of this trial and ultimately to providing orthopedic patients with a new option that could significantly contribute to the management of their postsurgical pain by replacing a perineural catheter, drug reservoir and pump with a single-dose injection of EXPAREL." The Full Research Report on Pacira Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/c8a5_PCRX] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquires, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. SOURCE Wall Street Reports Contact: +1-310-496-8071
Litigation Settlements, Data Compliance Reviews, and Clinical Trials Pave Way for Solid Footing in Healthcare - Research Report
Press spacebar to pause and continue. Press esc to stop.